Innoviva Net Worth 2006-2021 | INVA

Interactive chart of historical net worth (market cap) for Innoviva (INVA) over the last 10 years. How much a company is worth is typically represented by its market capitalization, or the current stock price multiplied by the number of shares outstanding. Innoviva net worth as of September 17, 2021 is $1.06B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.059B $0.337B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $434.939B 18.10
Roche Holding AG (RHHBY) Switzerland $319.781B 0.00
Pfizer (PFE) United States $249.329B 14.16
Novo Nordisk (NVO) Denmark $241.084B 33.46
Eli Lilly (LLY) United States $221.573B 28.77
AbbVie (ABBV) United States $190.996B 9.15
Novartis AG (NVS) Switzerland $188.736B 14.02
Merck (MRK) United States $182.183B 12.47
AstraZeneca (AZN) United Kingdom $175.360B 24.93
Sanofi (SNY) $121.515B 13.39
GlaxoSmithKline (GSK) United Kingdom $105.307B 13.21
Bayer (BAYRY) Germany $52.972B 7.13
H Lundbeck (HLUYY) Denmark $5.383B 10.32